SEC filing summary
Filing identity: The supplied filing is Owens & Minor, Inc.’s Form 10-Q, not an Accendra Health Inc. filing. It covers the quarter ended September 30, 2021, and was signed November 3, 2021. Confirm the issuer before relying on this summary.
Business context and reporting period
Owens & Minor is a global healthcare solutions company with Global Solutions (distribution and services) and Global Products (medical products manufacturing and sourcing) segments. The filing presents third-quarter and nine-month 2021 results against 2020. The 2020 comparison includes Movianto as discontinued operations through its June 2020 divestiture; continuing-operations comparisons are therefore more useful.
Financial results and liquidity
- Third quarter: Net revenue was $2.502 billion, up 14.4%. Gross margin was $328.8 million (13.14% of revenue), down from $344.3 million (15.74%). Operating income was $62.9 million versus $75.6 million; net income was $44.1 million versus $46.1 million. Diluted EPS was $0.58 versus $0.76.
- Nine months: Net revenue was $7.318 billion, up 19.6%. Gross margin was $1.172 billion (16.01% of revenue), versus $882.3 million (14.42%). Operating income was $306.5 million versus $108.5 million. Continuing-operations net income was $179.6 million versus $37.3 million; diluted continuing-operations EPS was $2.38 versus $0.61. Prior-year nine-month net loss of $20.9 million included a $58.2 million discontinued-operations loss.
- Segment operating income: Global Solutions generated $20.4 million in Q3 and $47.7 million for nine months, versus $11.0 million and $8.5 million, respectively. Global Products generated $51.3 million in Q3 and $310.2 million for nine months, versus $89.9 million and $160.3 million.
- Cash flow: Nine-month operating cash flow was $73.8 million, down from $268.2 million. Inventory growth used $284.2 million of cash; accounts receivable growth used $84.4 million. Capital expenditures were $32.6 million. Cash, cash equivalents and restricted cash totaled $56.1 million, down from $134.5 million at year-end 2020.
- Debt and liquidity: Total debt carrying value was $961.1 million, compared with $1.026 billion at year-end 2020; long-term debt was $959.5 million. The company had $278 million available under its $300 million revolving facility and reported compliance with debt covenants. Current assets were $2.398 billion and current liabilities $1.425 billion.
Material changes and management commentary
- Revenue growth reflected market-share gains, recovery in elective procedures, higher surgical and infection-prevention and PPE sales, elevated glove-cost pass-through, and Patient Direct performance. Global Products revenue increased 43.3% in Q3 and 64.0% for nine months.
- Q3 gross margin and Global Products operating income weakened mainly because glove cost pass-through timing and accelerating commodity, transportation, and labor inflation pressured results. Nine-month profitability improved with higher PPE sales, favorable product mix and cost-pass-through timing, productivity, and operating efficiencies.
- In March 2021, the company issued $500 million of 4.5% senior notes due 2029 and refinanced its credit arrangements, using proceeds in part to repay term-loan and revolving-credit borrowings. Nine-month debt-extinguishment loss was $40.4 million, including financing-cost write-offs and reclassification of terminated swap losses.
- Management said it believes cash generation and available credit and receivables-securitization financing will be sufficient for foreseeable needs. The filing provides no specific earnings or revenue guidance.
Risks, contingencies, and unusual items
- COVID-19 and the Delta variant could affect demand, elective procedures, labor availability, supply chains, costs, and operations. Management cautioned that PPE sales growth and related productivity gains may not persist as pandemic conditions normalize.
- Inflation and volatile polypropylene, nitrile, fuel, transportation, and labor costs may pressure margins. Management estimated that a 100-basis-point interest-rate increase would reduce annual pre-tax earnings by about $2.2 million based on period-end borrowings.
- The IRS challenged the company’s transfer-pricing treatment for 2015–2018. The company disputes the proposed adjustments and believes reserves are adequate, but stated an adverse outcome could materially affect financial results or cash flows.
- Q3 and nine-month exit and realignment charges were $6.4 million and $21.0 million, primarily including Fusion5 wind-down, leadership, IT restructuring, and U.S. operations reorganization costs. Additional Fusion5 wind-down costs could arise in 2021.
- The company disclosed cross-default provisions among debt agreements, leverage and interest-coverage covenant requirements, and substantial debt obligations. It also identified customer and supplier concentration, competition, foreign-exchange exposure, and cybersecurity and operational continuity as risks.
Important facts for investors to verify
- Verify that the intended filing is Owens & Minor’s, given the mismatch with the requested company, Accendra Health Inc.
- Review segment trends and whether Q3 margin pressure from inflation and glove pass-through timing continued after September 30, 2021.
- Assess the sustainability of PPE-related revenue and profitability as pandemic demand changes.
- Track operating cash flow, inventory and receivables working capital, and capacity under revolving and receivables financing.
- Monitor the IRS transfer-pricing dispute, debt covenant compliance, and upcoming debt maturities.